Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—General
Current Signal: BUY (auto-tracking)
0.33% $73.25
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 91 253 mill |
EPS: | 4.50 |
P/E: | 16.28 |
Earnings Date: | Apr 25, 2024 |
SharesOutstanding: | 1 245.77 mill |
Avg Daily Volume: | 7.53 mill |
RATING 2024-03-28 |
---|
S |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 16.28 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.84x |
Company: PE 16.28 | industry: PE 19.30 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 71.98 - 74.52 ( +/- 1.73%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-10 | Telman Deborah H | Buy | 54 980 | Non-qualified Stock Option (Right to Buy) |
2024-03-10 | Telman Deborah H | Buy | 10 815 | Restricted Stock Unit |
2024-03-10 | Telman Deborah H | Sell | 2 555 | Restricted Stock Unit |
2024-03-10 | Telman Deborah H | Buy | 2 555 | Common Stock |
2024-03-10 | Telman Deborah H | Sell | 846 | Common Stock |
INSIDER POWER |
---|
62.04 |
Last 99 transactions |
Buy: 1 293 733 | Sell: 313 353 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $73.25 (0.33% ) |
Volume | 8.24 mill |
Avg. Vol. | 7.53 mill |
% of Avg. Vol | 109.40 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:36 | sell | $73.74 | N/A | Active |
---|
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.